Stockholm, Sweden – Barnik Invest Group, today announced the appointment of Dr. Benedict Broennimann as Chief Scientific Officer.
Dr. Broennimann is a highly accomplished medical and business executive with over 20 years of experience in the Life sciences industry. His extensive expertise and leadership will be invaluable as Barnik Invest Group continues to identify and invest in innovative companies with the potential to transform healthcare.
“We are thrilled to welcome Dr. Broennimann, who has had a long-standing joint-venture partnership with our portfolio company BoniPharmex, to the Barnik Invest Group team,” said Hamid Bakhshi, CEO of Barnik Invest Group. “His deep scientific knowledge, coupled with his strong business acumen, will be instrumental in driving our investment strategy and supporting the growth of our portfolio companies.”
Prior to joining Barnik Invest Group, Dr. Broennimann served as the Chief Scientific Officer at Truelastin Inc. and held leadership positions at several other prominent companies in the healthcare industry, including Ostomycure AS, Leman Cardiovascular SA, and Hancock Jaffe Laboratories Inc. Dr. Broennimann is a certified specialist in both general surgery and pharmaceutical medicine, with over 10 years of clinical experience. He is also a Senior Partner at Dynalis Pharma & ME Ltd, an international Life Sciences Engineering and Food Supplement Development company.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: hamid.bakhshi@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
